Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216665611> ?p ?o ?g. }
- W3216665611 endingPage "40" @default.
- W3216665611 startingPage "29" @default.
- W3216665611 abstract "The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). One of the most common adverse events seen with mogamulizumab in MF/SS patients is rash. Because of the protean nature of MF/SS and the variable clinical and histopathological features of mogamulizumab-associated rash, healthcare providers may have difficulty distinguishing rash from disease, and may not be aware of appropriate treatment strategies for this generally manageable adverse event. The objective of this report was to combine results from published literature with experiences and recommendations from multiple investigators and institutions into clinical best practice recommendations to assist healthcare providers in identifying and managing mogamulizumab-associated rash. Optimal management, which includes biopsy confirmation and steroid treatment, requires a multidisciplinary approach among oncology, dermatology, and pathology practitioners. INFOGRAPHIC." @default.
- W3216665611 created "2021-12-06" @default.
- W3216665611 creator A5002599922 @default.
- W3216665611 creator A5004755576 @default.
- W3216665611 creator A5012935972 @default.
- W3216665611 creator A5015291923 @default.
- W3216665611 creator A5027978665 @default.
- W3216665611 creator A5046355746 @default.
- W3216665611 creator A5047163487 @default.
- W3216665611 creator A5067235495 @default.
- W3216665611 creator A5068469347 @default.
- W3216665611 creator A5069406522 @default.
- W3216665611 creator A5070592813 @default.
- W3216665611 creator A5075947127 @default.
- W3216665611 creator A5077671733 @default.
- W3216665611 creator A5079170974 @default.
- W3216665611 creator A5082463294 @default.
- W3216665611 creator A5089202009 @default.
- W3216665611 date "2021-11-23" @default.
- W3216665611 modified "2023-10-09" @default.
- W3216665611 title "Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management" @default.
- W3216665611 cites W1584810802 @default.
- W3216665611 cites W1594557237 @default.
- W3216665611 cites W1877715550 @default.
- W3216665611 cites W1906100218 @default.
- W3216665611 cites W1986493129 @default.
- W3216665611 cites W1996098672 @default.
- W3216665611 cites W2096850086 @default.
- W3216665611 cites W2110220145 @default.
- W3216665611 cites W2110890034 @default.
- W3216665611 cites W2127008679 @default.
- W3216665611 cites W2153633245 @default.
- W3216665611 cites W2166075265 @default.
- W3216665611 cites W2324052799 @default.
- W3216665611 cites W2332511670 @default.
- W3216665611 cites W2518731208 @default.
- W3216665611 cites W2600567499 @default.
- W3216665611 cites W2765390900 @default.
- W3216665611 cites W2768429453 @default.
- W3216665611 cites W2783230040 @default.
- W3216665611 cites W2803843055 @default.
- W3216665611 cites W2831487285 @default.
- W3216665611 cites W2885239461 @default.
- W3216665611 cites W2903888989 @default.
- W3216665611 cites W2911317946 @default.
- W3216665611 cites W2912166265 @default.
- W3216665611 cites W2924070172 @default.
- W3216665611 cites W2933704068 @default.
- W3216665611 cites W2943404462 @default.
- W3216665611 cites W2947286914 @default.
- W3216665611 cites W2950260751 @default.
- W3216665611 cites W2963138942 @default.
- W3216665611 cites W3026206930 @default.
- W3216665611 cites W3033554321 @default.
- W3216665611 cites W3087980837 @default.
- W3216665611 cites W3120181622 @default.
- W3216665611 cites W3155099789 @default.
- W3216665611 doi "https://doi.org/10.1007/s13555-021-00624-7" @default.
- W3216665611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34816383" @default.
- W3216665611 hasPublicationYear "2021" @default.
- W3216665611 type Work @default.
- W3216665611 sameAs 3216665611 @default.
- W3216665611 citedByCount "10" @default.
- W3216665611 countsByYear W32166656112022 @default.
- W3216665611 countsByYear W32166656112023 @default.
- W3216665611 crossrefType "journal-article" @default.
- W3216665611 hasAuthorship W3216665611A5002599922 @default.
- W3216665611 hasAuthorship W3216665611A5004755576 @default.
- W3216665611 hasAuthorship W3216665611A5012935972 @default.
- W3216665611 hasAuthorship W3216665611A5015291923 @default.
- W3216665611 hasAuthorship W3216665611A5027978665 @default.
- W3216665611 hasAuthorship W3216665611A5046355746 @default.
- W3216665611 hasAuthorship W3216665611A5047163487 @default.
- W3216665611 hasAuthorship W3216665611A5067235495 @default.
- W3216665611 hasAuthorship W3216665611A5068469347 @default.
- W3216665611 hasAuthorship W3216665611A5069406522 @default.
- W3216665611 hasAuthorship W3216665611A5070592813 @default.
- W3216665611 hasAuthorship W3216665611A5075947127 @default.
- W3216665611 hasAuthorship W3216665611A5077671733 @default.
- W3216665611 hasAuthorship W3216665611A5079170974 @default.
- W3216665611 hasAuthorship W3216665611A5082463294 @default.
- W3216665611 hasAuthorship W3216665611A5089202009 @default.
- W3216665611 hasBestOaLocation W32166656111 @default.
- W3216665611 hasConcept C126322002 @default.
- W3216665611 hasConcept C16005928 @default.
- W3216665611 hasConcept C197934379 @default.
- W3216665611 hasConcept C2777756187 @default.
- W3216665611 hasConcept C2778570526 @default.
- W3216665611 hasConcept C2779338263 @default.
- W3216665611 hasConcept C71924100 @default.
- W3216665611 hasConceptScore W3216665611C126322002 @default.
- W3216665611 hasConceptScore W3216665611C16005928 @default.
- W3216665611 hasConceptScore W3216665611C197934379 @default.
- W3216665611 hasConceptScore W3216665611C2777756187 @default.
- W3216665611 hasConceptScore W3216665611C2778570526 @default.
- W3216665611 hasConceptScore W3216665611C2779338263 @default.
- W3216665611 hasConceptScore W3216665611C71924100 @default.
- W3216665611 hasIssue "1" @default.